Presentation of regulatory capital components from the consolidated regulatory balance sheet

| | Consolidated regulatory balance sheet as of June 30, 2014 | References to regulatory capital components | |
|------------------------------------------------------------------------|-----------------------------------------------------------|---------------------------------------------|----|
| | NIS in millions | | |
| Assets | | | |
| Cash and deposits with banks | 27,181 | 1 | |
| Securities* | 9,744 | 4 | |
| * Includes: Investments in equity of financial corporations, not | | | |
| exceeding 10% of share capital of each financial corporation | | - | 14 |
| * Includes: Investments in equity of financial corporations, exceeding | | | |
| 10% of share capital of each financial corporation, not exceeding | | | |
| the deduction threshold | | - | |
| * Includes: Other securities | 9,744 | 4 | |
| Securities loaned or sold in repurchase agreements | 112 | 2 | |
| Loans to the public | 144,646 | 6 | |
| Provision for credit losses* | (1,293 |) | |
| * Includes: Group provision for credit losses included in Tier 2 | (1,178 |) | |
| * Includes: Provision for credit losses not included in regulatory | | | |
| capital | (115 |) | |
| Loans to the public, net | 143,353 | 3 | |
| Loans to Governments | 285 | 5 | |
| Investments in associates* | 6 | 1 | |
| * Includes: Investments in equity of financial corporations, exceeding | | | |
| 10% of share capital of each financial corporation, not exceeding | | | |
| the deduction threshold | | 3 | 21 |
| * Includes: Investments in other associates | 58 | 3 | |
| Buildings and equipment | 1,658 | 3 | |
| Intangible assets and goodwill* | 87 | 7 | |
| * Includes: Goodwill | 87 | 7 | 6 |
| * Includes: Other intangible assets | | - | 7 |
| Assets with respect to derivatives | 3,467 | 7 | |
| Other assets* | 2,210 |) | |
| * Includes: Deferred tax assets** | 789 | Э | |
| ** Includes: Deferred tax assets, other than those arising from | | | |
| temporary differences | | - | 9 |
| ** Includes: Deferred tax liability with respect to intangible assets | | - | 8 |
| ** Includes: Other deferred tax assets | 789 | 9 | |
| * Includes: Excess deposit over provision | | - | 12 |
| * Includes: Other additional assets | 1,42 | 1 | |
| Total assets | 188,158 | 3 | |

| | Consolidated regulatory | References to | |
|------------------------------------------------------------------------|--------------------------|---------------|--|
| | balance sheet as of June | | |
| | 30, 2014 | | |
| | NIS in millions | • | |
| Liabilities and Shareholders' Equity | | | |
| Deposits from the public | 148,063 | 3 | |
| Deposits from banks | 1,523 | 3 | |
| Deposits from the Government | 56 | 3 | |
| Debentures and subordinated notes* | 19,120 |) | |
| * Includes: Subordinated notes not recognized as regulatory capital | 2,776 | 3 | |
| * Includes: Subordinated notes recognized as regulatory capital** | 3,573 | 3 | |
| ** Includes: Qualifying as regulatory capital components | | - a16,a18 | |
| ** Includes: Not qualifying as regulatory capital components and | | | |
| subject to transitional provisions | 3,573 | b16,b18 | |
| Liabilities with respect to derivatives* | 3,303 | 3 | |
| * Includes: With respect to own credit risk | 24 | 11 | |
| Other liabilities* | 5,176 | 3 | |
| * Includes: Deferred tax liability arising from retirement | | - 13 | |
| Total liabilities | 177,241 | | |
| Equity attributable to equity holders of the banking corporation* | 10,418 | 3 | |
| * Includes: Ordinary share capital** | 10,307 | | |
| ** Includes: Ordinary share capital | 2,046 | 5 1 | |
| ** Includes: Retained earnings | 8,259 | | |
| ** Includes: Cumulative other comprehensive loss*** | 2 | | |
| *** Includes: Net loss from cash flow hedges | g |) | |
| *** Includes: Adjustments for presentation of securities available for | | | |
| sale at fair value | (3 |) | |
| *** Includes: Net change from translation of financial statements | (4 | | |
| * Includes: Capital reserves | 111 | | |
| * Includes: Preferred share capital** | | - | |
| ** Includes: Qualifying as regulatory capital components | | - a15 | |
| ** Includes: Not qualifying as regulatory capital components and | | | |
| subject to transitional provisions | | - b15 | |
| * Includes: Other equity instruments** | | | |
| ** Includes: Qualifying as regulatory capital components | | - | |
| ** Includes: Not qualifying as regulatory capital components and | | | |
| subject to transitional provisions | | - | |
| Non-controlling interest* | 499 |) | |
| * Includes: Non-controlling interest attributable to Tier 1 equity | 460 | | |
| * Includes: Non-controlling interest attributable to additional Tier 1 | 400 | | |
| equity | | - 17 | |
| * Includes: Non-controlling interest attributable to Tier 2 equity | | - 19 | |
| * Includes: Non-controlling interest not attributable to regulatory | | 13 | |
| capital | 39 |) | |
| Total shareholders' equity | 10,917 | | |
| Total liabilities and shareholders' equity | 188,158 | | |